

FDA-University of Maryland CERSI

ADEPT 8: Workshop on drug dosing in Pediatric Patients with Renal Impairment

Agenda

Day 1 – Thursday, November 30, 2023

- 9:00 – 9:05 a.m.** Welcome - Lily Mulugeta (FDA) and Bakri Alzarka (Univ. of Maryland)
- 9:05 - 9:15 a.m.** Introductory remarks – Peter Stein (FDA)
- 9:15 - 9:25 a.m.** Setting the scene - Shamir Tuchman (FDA)
- 9:25 – 9:35 a.m.** Opening presentation - Martina Sahre (FDA)
- 9:35 - 9:45 a.m.** Drug clearance in pediatric patients with renal impairment - Saskia de Wildt (Radboud Univ. Medical Center)
- 9:45 – 9:55 a.m.** Case example: Avycaz (Abbvie) - Henrietta Abodakpi (FDA)

Session 1: What constitutes as renal impairment in pediatric patients for the purposes of PK characterization and drug dosing?

Academic Perspective: Considerations around assessment of renal function

- 9:55 – 10:10 a.m.** Strengths and limitations of existing estimation methods and applications to specific population - George Schwartz (Univ. of Rochester Medical Center)

Clinical Perspective: Considerations around assessment of renal function and drug dosing

- 10:10 – 10:30 a.m.** What clinicians and other stakeholders need to know about special populations
Guido Filler (Western Univ. – London, Ontario, Canada; Children's Hospital, London Health Sciences Centre)

Industry Perspective: Considerations around assessment of renal function in the context of clinical trial

- 10:30 – 10:45 a.m.** Speaker 1: Ashish Sharma (Boehringer-Ingelheim)
- 10:45 – 11:10 a.m.** Speakers 2 and 3: Nicholas Webb and Deepa Chand (Novartis)

11:10 – 11:30 a.m. BREAK

11:30 a.m. -1:00 p.m. Moderated Panel Discussion and Q&A

Moderators: Mona Khurana (FDA) and Bakri Alzarka (Univ. of Maryland)

Panelists:

- Shamir Tuchman (FDA)
- Martina Sahre (FDA)
- Deepa Chand (Novartis; Univ. of Illinois College of Medicine)
- Nicholas Webb (Novartis)
- Afshin Parsa (NIH)
- George Schwartz (Univ. of Rochester Medical Center)
- Guido Filler (Western Univ. – London, Ontario, Canada)

1:00 - 2:00 p.m. LUNCH

Session 2: Translating adult renal impairment data in pediatric patients with renal impairment

2:00 – 2:10 p.m. Recap of Case Example: Avycaz (Abbie) - Henrietta Abodakpi (FDA)

**2:10 – 2:25 p.m. Translating adult renal impairment PK data—Academic/clinical perspective
Saskia de Wildt (Radboud Univ. Medical Center)**

2:25 -2:40 p.m. Reliance on BSA indexed GFR values versus individualized eGFR values to guide drug dosing in adults and implications to pediatrics - Thomas Nolin (Univ. of Pittsburgh School of Pharmacy)

2:40 – 4:30 p.m. Moderated Panel Discussion and Q&A

Moderators: Lily Mulugeta (FDA) and Tsuyoshi Fukuda (Eli Lilly)

Panelists:

- Lynne Yao (FDA)
- Martina Sahre (FDA)
- Vikram Sinha (Novartis)
- Rebecca Wrishko (Merck)
- Saskia de Wildt (Radboud Univ. Medical Center)
- George Schwartz (Univ. of Rochester Medical Center)
- Jeff Barrett (Aridhia)
- Thomas Nolin (Univ. of Pittsburgh School of Pharmacy)

4:30 – 4:40 p.m. Summary and closing - Lily Mulugeta (FDA) and Bakri Alzarka (UMD)

Day 2 – Friday, December 1, 2023

Session 3: Future Directions: Dosing in pediatric patients with renal impairment

Role of modeling and simulation

9:00 - 9:10 a.m. Considerations for modeling and simulation for pediatric renal impairment - **Justin Earp (FDA)**

9:10 – 9:20 a.m. Role of systems biology modeling in extrapolating efficacy and safety from adult renal impairment data – **Karim Azer (Rutgers Univ.)**

9:20 – 10:30 a.m. Moderated Panel Discussion and Q&A

Moderators: Elimika Pfuma Fletcher (FDA) and Jeff Barrett (Aridhia)

Panelists:

- Jason Moore (FDA)
- Hao Zhu (FDA)
- Saskia de Wildt (Radboud Univ. Medical Center)
- Sonya Tang Girdwood (Cincinnati Children's)
- Liping Zhang (Johnson & Johnson)
- Karim Azer (Rutgers Univ.)
- Efthymios Manolis (EMA)
- Pieter Colin (EMA)

10:30 – 10:45 a.m. BREAK

Approaches for generating clinical trial data to assess impact of RI on PK in pediatric patients

10:45 – 10:55 a.m. Industry perspective; **Jan Marquard (Boehringer-Ingelheim)**

Labeling considerations

10:55 – 11:05 a.m. **Su-Young Choi (FDA)**

11:05 a.m. - 12:05 p.m. Moderated Panel Discussion and Q&A

Moderators: Lynne Yao (FDA) and Bakri Alzarka (Univ. of Maryland)

Panelists:

- Kirtida Mistry (FDA)

- Gil Burckart (FDA)
- Bradley Warady (Children's Mercy Kansas City)
- Adam Levy (BMS Pediatric Center of Excellence)
- Ashish Sharma (Boehringer-Ingelheim)
- Jan Marquard (Boehringer-Ingelheim)
- Susan Mendley (NIH)
- Guido Filler (Western University; Children's Hospital, London Health Sciences Centre)

12:05 – 12:15 p.m. Summary and Closing Remarks - Lynne Yao, FDA